<DOC>
	<DOCNO>NCT02262273</DOCNO>
	<brief_summary>This study carry retrospective , non-interventional observational review medical record patient multiple country platinum-sensitive recurrent serous ovarian cancer . The objective describe real-world population , treatment pattern , BRCA mutation test result , overall survival , health care utilization also estimate rate select treatment- and/or disease-related side effect</brief_summary>
	<brief_title>OSCA - Olaparib Standard CAre Study</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . First determine platinumsensitive recurrent serous ovarian cancer January 1 , 2009 , December 31 , 2013 ( study entry period ) , define evidence disease progression least 6 month completion firstline platinumbased chemotherapy regimen ; first date platinumsensitive recurrence January 1 , 2009 December 31 , 2013 define study index date . 2 . At least 18 year age index date . 3 . Fully documented medical history relate patient 's ovarian cancer treatment begin initial diagnosis serous ovarian cancer . 4 . Patients either alive deceased time medical record abstraction . 1 . Ever take investigational product part interventional clinical trial ovarian cancer .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>woman</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>recurrent</keyword>
	<keyword>serous</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>BRCA</keyword>
	<keyword>PARP</keyword>
	<keyword>Olaparib</keyword>
</DOC>